Parathyroid Hormone

證據等級: L5

預測適應症: 10 個

Parathyroid Hormone: From No Established Indication to Predicted Migraine Disorder

One-Sentence Summary

Parathyroid Hormone (PTH, DrugBank ID DB05829) has no marketing authorization or approved indication recorded in Norway, and its original mechanism of action is not documented in the available data. The TxGNN model predicts potential relevance to Migraine Disorder, but the current supporting evidence is indirect — 1 tangentially related clinical trial and 6 literature references, most of which discuss PTH/PTHrP-related genetics or comorbid endocrine mechanisms rather than direct therapeutic evidence for migraine.

Quick Overview

Item	Content
Original Indication	Not available (drug not marketed in Norway; no approved indication text on file)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.98%
Evidence Level	L4
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Parathyroid Hormone. Based on the evidence pack, no original indication or MOA record exists in the Norway regulatory dataset, and the drug is not currently marketed there — so a direct mechanistic bridge between an "original indication" and migraine cannot be established from the provided data.

The strongest supporting signal is a 2025 genetic/mechanistic study identifying PTHrP (parathyroid hormone-related peptide) receptors as one of several genetic drivers associated with migraine susceptibility (PMID 40297711). This is a receptor-family association at the genomic level, not evidence that exogenous PTH administration treats migraine. A small number of older publications describe central nervous system effects of calcitonin/parathormone (PMID 3739765) and comorbid calcium/vitamin D/magnesium metabolism in migraine patients, but these describe correlative or physiological relationships rather than a therapeutic rationale for PTH itself.

Overall, the mechanistic link is plausible at the level of shared gene families and calcium-regulatory physiology, but it falls well short of establishing that PTH treatment would be clinically effective for migraine. This is reflected in the low evidence level (L4) assigned to this prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07028684	N/A	Completed	22	Studied foot reflexology massage (not PTH) for pain, sleep, and quality of life in women with migraine; disease-population overlap only, no PTH intervention (relevance grade C).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24714817	2014	RCT (add-on Vitamin D)	Braz J Med Biol Res	Vitamin D supplementation added to amitriptyline reduced migraine attack frequency in pediatric patients; PTH/calcium axis not directly tested.
40297711	2025	Review/Genetic	Brain Communications	Identifies PTHrP receptor genes as candidate genetic drivers of migraine susceptibility in a Portuguese cohort.
29429076	2018	Review	Neuromolecular Medicine	Reviews cardiovascular autonomic dysfunction linking bone remodeling mediators (including PTH) to neurodegeneration in MS; not migraine-specific.
11425281	2001	Review	Medical Hypotheses	Broad review of magnesium deficiency pathology, including its role in numerous conditions; PTH mentioned only in the context of mineral metabolism.
31261815	2019	Cohort	Medicina (Kaunas)	Evaluated vitamin D levels and response to therapy in childhood migraine; PTH not a treatment variable.
3739765	1986	Animal/Mechanistic	Acta Neurologica	Early study of central nervous system effects of calcitonin and parathormone; no abstract available, direct relevance unclear.

Norway Market Information

Currently not marketed in Norway — no authorization or license records are available in the dataset.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for PTH in migraine is limited to a single genetic association study on PTHrP receptors and a handful of indirect or mechanistic publications, with no clinical trial directly testing PTH administration for migraine. Combined with the complete absence of Norway market authorization, MOA data, and safety/warning information, this candidate does not currently meet the threshold to proceed.

To proceed, the following is needed:

Detailed mechanism of action (MOA) data for Parathyroid Hormone
TFDA/Norway package insert warnings, contraindications, and drug interaction data
Direct pharmacological or clinical evidence linking PTH administration (not just PTHrP receptor genetics) to migraine pathophysiology or outcomes
Confirmation of route compatibility and dosage form suitability, given the drug is not currently marketed in Norway
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.